First test of ZP6590 injections in adults of normal weight, overweight or obesity
Checks the safety of ZP6590 and how the body handles it.
Plain-language title generated from the registry record
Registry title: A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
Key facts
- Where
- Neuss, GermanySee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07721597, who can take part
Where in Germany
- Profil Institut für Stoffwechselforschung GmbHNeuss, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zealand Pharma
- Trial code
- NCT07721597
- Record updated
- 13 August 2026
- Original description
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults. The main questions it aims to answer are:Read full original descriptionShow less
A First-in-human, Randomized, Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults. The main questions it aims to answer are:
* Is the drug ZP6590 safe and well tolerated when administered as escalating single and multiple doses of the ZP6590? * How quickly and to what extent the administered investigational drug is absorbed and distributed, and how long it takes to be eliminated from the body?
In the first Part of the study:
Participants will:
• Get a single ascending dose of the drug ZP6590 or placebo and will have an observation period of 4 weeks.
In the second Part of the study:
Participants will:
• Get multiple dosages of the drug ZP6590 or placebo for 6 or 12 weeks followed by an observation period of 6 weeks after last dosing.
Inclusion: SAD-Part:; Male participant; Age between 18 and 55 years, both inclusive; Body Mass Index (BMI) between 20.0 and 29.9 kg/m\^2, both inclusive; MAD-Part:; Male participant; Age between 18 and 60 years, both inclusive; Body Mass Index (BMI) between 27.0 and 39.9 kg/m\^2, both inclusive.
Exclusion: Treatment for weight management within 3 months before randomization in this trial; SAD-Part and MAD-Part:; Any clinically significant abnormal haematology, biochemistry, or urinalysis screening tests, as judged by the investigator.